Allarity Therapeutics (ALLR) Total Debt (2020 - 2026)

Allarity Therapeutics' (ALLR) quarterly Total Debt came in at $20.1 million in Q1 2026, up 7932.0% on a QoQ basis from $250000.0 in Q4 2023.

Allarity Therapeutics (ALLR) Total Debt (2020 - 2026) Analysis & Trends

Allarity Therapeutics (ALLR) has 5 years of Total Debt data on file, last reported at $20.1 million in Q1 2026.

Quarterly Total Debt changed N/A year-over-year to $20.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.1 million (changed N/A YoY) and the FY2023 annual result came in at $250000.0, down 90.54% from the prior year.
Total Debt improved to $20.1 million in Q1 2026, from $250000.0 in the prior quarter.
In the past five years, Total Debt ranged from a high of $20.1 million in Q1 2026 to a low of $250000.0 in Q4 2023.
A 3-year average of $4.4 million and a median of $1.5 million in 2022 frame the typical range for Total Debt.
Annual changes were most pronounced in 2022 — Total Debt decreased 0.86% — and 2023, when it tumbled 90.54%.
Tracing ALLR's Total Debt over 3 years: stood at $2.6 million in 2022, then plunged by 90.54% to $250000.0 in 2023, then surged by 7932.0% to $20.1 million in 2026.
The last three Total Debt figures came in at $20.1 million (Q1 2026), $250000.0 (Q4 2023), and $351000.0 (Q3 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	138.57 Bn	130.72 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.98 Bn	77.99 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	65.11 Bn	59.92 Bn	1.37 Bn	-
4	Moderna	55.73 Bn	50.59 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.99 Bn	36.89 Bn	1.53 Bn	1.07 Bn
6	Alnylam Pharmaceuticals	31.64 Bn	28.33 Bn	992.69 Mn	-
7	BioNTech SE	27.70 Bn	9.31 Bn	668.28 Mn	770.36 Mn
8	Insmed	27.46 Bn	26.30 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.32 Bn	26.49 Bn	-	9.34 Bn
10	Allarity Therapeutics	22.91 Mn	22.91 Mn	-	20.86 Mn

Download Data